| ￥5800 | |
| Z04416-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized BTLA[Biotin], His & Avi, Human at 2μg/ml(100μl/well) on the streptavidin precoated plate (5μg/ml) can bind Human HVEM, hFc Tag. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 16.7 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 38-50 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized BTLA[Biotin], His & Avi, Human, His Tag at 2 μg/ml(100 μl/well) on the streptavidin precoated plate(5 μg/ml). Dose response curve for Human HVEM, hFc Tag with the EC50 of 8.6 ng/ml determined by ELISA. »
Immobilized Anti-BTLA Antibody, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for BTLA[Biotin], His & Avi, Human, His Tag with the EC50 of 7.8 ng/ml determined by ELISA. »
The purity of BTLA[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC »
BTLA[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | B- and T-lymphocyte attenuator (BTLA; CD272) is a 35 kDa type I transmembrane glycoprotein in the CD28 family of T cell costimulatory molecules. BTLA is a inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. BTLA may interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14. |
| Synonyms | CD272; BTLA; BTLA1; FLJ16065; MGC129743 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
